After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal
Nine years ago, when Michael Morrissey took over the helm at Exelixis as George Scangos headed to Biogen, he made a careful point of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
